目次

Table of Contents

List of Tables

List of Figures
Introduction
Global Markets Direct Report Coverage
Dilated Cardiomyopathy - Overview
Dilated Cardiomyopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Dilated Cardiomyopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dilated Cardiomyopathy - Companies Involved in Therapeutics Development
Avery Therapeutics Inc
Berlin Cures Holding AG
BioMarin Pharmaceutical Inc
BridgeBio Pharma Inc
Bristol-Myers Squibb Co
Cardior Pharmaceuticals GmbH
Celixir Ltd
CellServe GmbH
DiNAQOR AG
Dynomics Inc
Heartseed Inc
Help Therapeutics
iHeart Japan Corp
Martin Pharmaceuticals Inc
Maze Therapeutics Inc
NeoProgen Inc
Nuevocor Pte Ltd
Olagenesis Corp
Pfizer Inc
Recursion Pharmaceuticals Inc
Renovacor Inc
Shionogi & Co Ltd
Tenaya Therapeutics Inc
Dilated Cardiomyopathy - Drug Profiles
BC-007 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CDR-426D - Drug Profile
Product Description
Mechanism Of Action
Cell Therapy for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
danicamtiv - Drug Profile
Product Description
Mechanism Of Action
History of Events
DINA-005 - Drug Profile
Product Description
Mechanism Of Action
DINA-006 - Drug Profile
Product Description
Mechanism Of Action
DINA-008 - Drug Profile
Product Description
Mechanism Of Action
DINA-009 - Drug Profile
Product Description
Mechanism Of Action
DINA-010 - Drug Profile
Product Description
Mechanism Of Action
DINA-011 - Drug Profile
Product Description
Mechanism Of Action
DYN-101 - Drug Profile
Product Description
Mechanism Of Action
emprumapimod - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for Dilated Cardiomyopathy and Heart Failure - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate BAG3 for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
Heartcel - Drug Profile
Product Description
Mechanism Of Action
History of Events
HS-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IHJ-301 - Drug Profile
Product Description
Mechanism Of Action
MyCardia - Drug Profile
Product Description
Mechanism Of Action
Neo-2001 - Drug Profile
Product Description
Mechanism Of Action
NovoCardia - Drug Profile
Product Description
Mechanism Of Action
redasemtide trifluoroacetate - Drug Profile
Product Description
Mechanism Of Action
REN-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
History of Events
Stem Cell Therapy for Myocardial Infarction and Dilated Cardiomyopathy - Drug Profile
Product Description
Mechanism Of Action
History of Events
TN-301 - Drug Profile
Product Description
Mechanism Of Action
History of Events
trimetazidine - Drug Profile
Product Description
Mechanism Of Action
History of Events
YS-1402 - Drug Profile
Product Description
Mechanism Of Action
Dilated Cardiomyopathy - Dormant Projects
Dilated Cardiomyopathy - Product Development Milestones
Featured News & Press Releases
Jul 13, 2021: Tenaya Therapeutics unveils preclinical research supporting product candidate for rare and prevalent heart disease indications at ESC Heart Failure 2021
Sep 09, 2020: MyoKardia doses first patient in phase 2 clinical trial of danicamtiv in genetic dilated cardiomyopathy
Mar 26, 2020: MyoKardia Provides clinical trial update on Danicamtiv study
Oct 28, 2019: MyoKardia Announces Positive MYK-491 Data; Advancing Program into Targeted Genetic Dilated Cardiomyopathy Population
May 30, 2019: MyoKardia's MYK-491 shows favourable profile in Phase Ia study
Apr 15, 2019: Berlin Cures announces start of Phase IIa for its DNA-based neutralizer of B1-adrenoceptor autoantibodies
Dec 11, 2018: MyoKardia reports positive data from phase 1b single-ascending dose clinical trial of MYK-491 in dilated cardiomyopathy and systolic heart failure patients
Dec 06, 2018: Berlin Cures steering committee is assembled to facilitate the design and implementation of phase 2 study of BC
Oct 30, 2018: MyoKardia Shares Data from new research program ACT-1 at 2018 R&D Day
Feb 26, 2018: Heart Failure Treatment from Berlin Cures Shows Promise in Phase 1 Study
Feb 14, 2018: MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
Nov 02, 2017: MyoKardia Provides Update on MYK-491
Sep 27, 2017: MyoKardia Provides Update on MYK-491 Clinical Progress
Feb 02, 2017: First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491
Dec 02, 2016: MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Dilated Cardiomyopathy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Dilated Cardiomyopathy - Pipeline by Avery Therapeutics Inc, 2022
Dilated Cardiomyopathy - Pipeline by Berlin Cures Holding AG, 2022
Dilated Cardiomyopathy - Pipeline by BioMarin Pharmaceutical Inc, 2022
Dilated Cardiomyopathy - Pipeline by BridgeBio Pharma Inc, 2022
Dilated Cardiomyopathy - Pipeline by Bristol-Myers Squibb Co, 2022
Dilated Cardiomyopathy - Pipeline by Cardior Pharmaceuticals GmbH, 2022
Dilated Cardiomyopathy - Pipeline by Celixir Ltd, 2022
Dilated Cardiomyopathy - Pipeline by CellServe GmbH, 2022
Dilated Cardiomyopathy - Pipeline by DiNAQOR AG, 2022
Dilated Cardiomyopathy - Pipeline by Dynomics Inc, 2022
Dilated Cardiomyopathy - Pipeline by Heartseed Inc, 2022
Dilated Cardiomyopathy - Pipeline by Help Therapeutics, 2022
Dilated Cardiomyopathy - Pipeline by iHeart Japan Corp, 2022
Dilated Cardiomyopathy - Pipeline by Martin Pharmaceuticals Inc, 2022
Dilated Cardiomyopathy - Pipeline by Maze Therapeutics Inc, 2022
Dilated Cardiomyopathy - Pipeline by NeoProgen Inc, 2022
Dilated Cardiomyopathy - Pipeline by Nuevocor Pte Ltd, 2022
Dilated Cardiomyopathy - Pipeline by Olagenesis Corp, 2022
Dilated Cardiomyopathy - Pipeline by Pfizer Inc, 2022
Dilated Cardiomyopathy - Pipeline by Recursion Pharmaceuticals Inc, 2022
Dilated Cardiomyopathy - Pipeline by Renovacor Inc, 2022
Dilated Cardiomyopathy - Pipeline by Shionogi & Co Ltd, 2022
Dilated Cardiomyopathy - Pipeline by Tenaya Therapeutics Inc, 2022
Dilated Cardiomyopathy - Dormant Projects, 2022

List of Figures
Number of Products under Development for Dilated Cardiomyopathy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022